Yale University
New Haven, Connecticut, 06511, United States
NCT Number: NCT06108102
The International Post-Stroke Epilepsy Research Repository (IPSERR): The study aims to collate and categorize data reported by post-stroke epilepsy (PSE) researchers and lodge it within the IPSERR. Using the IPSERR database, we will conduct two individual patient data (IPD) analyses: (1) determine epilepsy, functional, and cognitive outcomes in stroke patients who develop post-stroke seizure and (2) build and validate post-stroke epilepsy prediction model and compare performance against existing models.
Interested in participating?
Request Info18 year and older
All sexes
Observational
New Haven, Connecticut, 06511, United States
The cerebrovascular disease is the most common cause of late-onset epilepsy. PSE is associated with increased morbidity, including cognitive decline, dependence, and poor quality of life, and is a critical determinant factor of stroke prognosis. We recently reported a systematic review and meta-analysis of 71 papers that suggested that post-stroke seizures are associated with more significant mortality and poor functional and cognitive outcomes (PMID:37721736). In this study, we observed disparate methods used by the individual investigators. We also noted variations in study reporting. PI aims to analyze existing individual patient data, including those analyzed in the systematic review, by collaborating with colleagues in the field and developing IPSERR into a resource for future collaborative studies that will tackle anti-epileptogenesis drug trial design.
Design and Rationale:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
Time frame: At 1 year, 2 year, and 5 year follow-up
The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death).
Time frame: At 1 year, 2 year, and 5 year follow-up
The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death), with 0-2 indicating a good functional outcome and 3-6 indicating a poor functional outcome.
Time frame: At 1 year, 2 year, and 5 year follow-up
Number of seizures post-stroke identified clinically or based on an electroencephalogram (EEG).
Time frame: At 1 year, 2 year, and 5 year follow-up
Defined by impaired awareness and the presence of bilateral tonic or clonic seizures.
Time frame: At 1 year, 2 year, and 5 year follow-up
Status epilepticus is defined as a seizure or series of seizures lasting more than 30 minutes without recovery of consciousness based on electroencephalogram (EEG) findings.
Time frame: At 1 year, 2 year, and 5 year follow-up
The duration of hospital admission for a stroke is measured in days.
Time frame: At 1 year, 2 year, and 5 year follow-up
MMSE is tests cognitive function. It is scored out of 30, with a score of ≤26 indicating cognitive impairment. MoCA assesses mild cognitive dysfunction. It is scored out of 30, with a score of ≤24 indicating cognitive impairment.
Time frame: At 1 year, 2 year, and 5 year follow-up
A diagnosis of a subsequent stroke will be made based on neuroimaging.
Time frame: At 1 year, 2 year, and 5 year follow-up
Switching of antiseizure medication (ASM) defined as discontinuation of one ASM and starting of another due to adverse events or treatment ineffectiveness.
Time frame: At 1 year, 2 year, and 5 year follow-up
Adverse events are defined as any side effects occurring due to antiseizure medication administration during the course of the study.
Time frame: At 1 year, 2 year, and 5 year follow-up
HAM-D is a tool used to assess depression symptoms. Depression post-ASM administration is defined as HAM-D score of 0-13 mild; 14-17 mild to moderate; >17 moderate to severe depression.
Time frame: At 1 year, 2 year, and 5 year follow-up
HAM-A is a psychological questionnaire that measures the severity of a patient's anxiety. Anxiety post-ASM administration is defined as HAM-A score of <17 mild; 18-24 moderate; 25-30 moderate to severe anxiety.
Yale University
Other
International Post Stroke Epilepsy Research Repository to Characterize Post-stroke Epilepsy Population and Their Outcomes
Acronym: IPSERR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05864547
Brain Diseases, Cardiovascular Diseases
Trondheim, Norway
View Trial DetailsNCT06597084
Brain Diseases, Central Nervous System Diseases
Klagenfurt, FeschnigstraBe 11, Austria
View Trial DetailsNCT02670161
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Evanston, Illinois, United States
View Trial DetailsNCT06583395
Adnexal Diseases, Amyotrophic Lateral Sclerosis
Palm Desert, California, United States
View Trial Details